Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial

PURPOSE: Given between-country differences in healthcare systems, treatment costs, and disease management guidelines, country-specific cost-effectiveness analyses are important. This study evaluated the cost-effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus...

Descripción completa

Detalles Bibliográficos
Autores principales: Paly, Victoria Federico, Vallejo-Aparicio, Laura Amanda, Martin, Alan, Izquierdo, José Luis, Riesco, Juan Antonio, Soler-Cataluña, Juan José, Abreu, Catarina, Biswas, Chandroday, Ismaila, Afisi S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766529/
https://www.ncbi.nlm.nih.gov/pubmed/36561129
http://dx.doi.org/10.2147/COPD.S366765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766529/
https://www.ncbi.nlm.nih.gov/pubmed/36561129
http://dx.doi.org/10.2147/COPD.S366765

Ejemplares similares